{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:22:57Z","timestamp":1791087777421,"version":"4.1.0"},"reference-count":37,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2010,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Beta lactam agents are the most active drugs for the treatment of streptococci and methicillin-susceptible\n            <jats:italic>Staphylococcus aureus<\/jats:italic>\n            endocarditis. However, methicillin-resistant\n            <jats:italic>S. aureus<\/jats:italic>\n            (MRSA) is resistant to all beta lactam agents licensed to date, and alternative treatments are limited. Ceftobiprole is a novel broad-spectrum cephalosporin that binds with high affinity to PBP 2a, the penicillin binding protein that mediates the methicillin resistance of staphylococci and is active against MRSA. Ceftobiprole was compared to vancomycin, daptomycin, and linezolid in a rabbit model of MRSA aortic valve endocarditis caused by the homogeneously methicillin-resistant laboratory strain COL. Residual organisms in vegetations were significantly fewer in ceftobiprole-treated rabbits than in any other treatment group (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05 for each comparison). In addition, the numbers of organisms in spleens and in kidneys were significantly lower in ceftobiprole-treated rabbits than in linezolid- and vancomycin-treated animals (\n            <jats:italic>P<\/jats:italic>\n            &lt; 0.05 for each comparison). Anti-MRSA beta lactam agents such as ceftobiprole may represent a significant therapeutic advance over currently available agents for the treatment of MRSA endocarditis.\n          <\/jats:p>","DOI":"10.1128\/aac.00886-09","type":"journal-article","created":{"date-parts":[[2009,11,17]],"date-time":"2009-11-17T02:57:00Z","timestamp":1258426620000},"page":"610-613","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":36,"title":["Ceftobiprole Is Superior to Vancomycin, Daptomycin, and Linezolid for Treatment of Experimental Endocarditis in Rabbits Caused by Methicillin-Resistant\n            <i>Staphylococcus aureus<\/i>"],"prefix":"10.1128","volume":"54","author":[{"given":"P.","family":"Tattevin","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Basuino","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bauer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. A.","family":"Diep","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, San Francisco General Hospital, University of California, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00126839-200607050-00003"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000153812.64956.EF"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/533590"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/520655"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.4.419"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.5.1598-1603.2003"},{"key":"e_1_3_2_8_2","first-page":"17","volume":"12","year":"2006","unstructured":"Chambers, H. F. 2006. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect.12(Suppl. 2):17-22.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0702.010204"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.884-888.2005"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.5.3.333"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.9.3002-3004.2003"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1086\/533595"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.8.2304-2308.2001"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.1.171-177.2002"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.24.3012"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.1.75"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.03.013"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.12.3706-3711.2002"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01501-05"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01242-06"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.1.45-51.2005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.11.2081"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00510-07"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1086\/519471"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.47.4.1262-1266.2003"},{"key":"e_1_3_2_28_2","first-page":"25","volume":"13","year":"2007","unstructured":"Noel, G. J. 2007. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic. Clin. Microbiol. Infect.13(Suppl. 2):25-29.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1086\/526527"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00551-07"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/47.3.349"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.50.4.1581-1585.2006"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1086\/533592"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1086\/524667"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm258"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1086\/510386"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.35.1.124"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1086\/526528"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00886-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00886-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:54:10Z","timestamp":1645473250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00886-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["10.1128\/AAC.00886-09"],"URL":"https:\/\/doi.org\/10.1128\/aac.00886-09","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"2009-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-11-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-02-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}